Inventor profile of:

Niklas Bergh

City:

Askim

Country:

Sweden

Published Applications:

12

Last publication date:

2025-07-31

Top Assignees for applications by Niklas Bergh

The entities that hold a legal rights for patent applications filed by inventor Bergh Niklas:

Recent patent applications by Bergh Niklas

Niklas Bergh from Askim, SE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-07-31
US20250241880A1
Human necessities

VALPROIC ACID FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION

#2 | 2023-11-16
US20230364089A1
Human necessities

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION

#3 | 2023-04-20
US20230120670A1
Human necessities

Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

#4 | 2023-03-30
US20230094176A1
Human necessities

COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS

#5 | 2022-12-22
US20220401393A1
Human necessities

Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation

#6 | 2021-03-04
US20210060014A1
Human necessities

COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS

#7 | 2020-06-11
US20200179381A1
Human necessities

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION

#8 | 2019-04-18
US20190111011A1
Human necessities

Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

#9 | 2019-01-17
US20190015360A1
Human necessities

Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation

#10 | 2018-06-28
US20180177751A1
Human necessities

Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation

#11 | 2017-01-26
US20170020874A1
Human necessities

COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS

#12 | 2014-02-20
US20140051716A1
Human necessities

COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS

InventorID:

659202 ⎘